ANDS: Another stock you don't like Dew? How timely!
Anadys Pharma profiled in Inside Wall Street - Business Week Online (9.35 )
Business Week Online reports some analysts think Anadys' (ANDS) decline has been overdone, and they're betting on a rebound. By summer's end, they expect the co to report favorable results from early trials of an oral drug for chronic hepatitis C virus and perhaps other diseases such as hepatitis B. Anadys has a global partnership with Novartis (NVS) for them to develop, manufacture, and sell the drug, which would cause a stir in the $3 bln hepatitis C market. "This is a very good company with very good science," says Eric Schmidt of Cowen. "If those data are as good as we hope, the stock might be a two- or three-bagger." Schmidt expects more losses like those in Q1, when the co lost $5.8 mln (vs. $8.4 mln for Q105). Soham Pandya of Susquehanna Financial Group rates the stock a "buy." He argues that "earnings are not material" because Anadys will "incur operating losses as it funds R&D." It has a strong pipeline of new drugs, with about 45 issued patents and 92 pending worldwide
Market Data 
Markets 
AI
